75
Participants
Start Date
June 30, 2002
Primary Completion Date
December 31, 2002
Study Completion Date
December 31, 2002
Pramlintide acetate
Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
Orlando Clinical Research Center, Orlando
New Orleans Center for Clinical Research, New Orleans
DaVita Clinical Research, Minneapolis
CEDRA Clinical Research, LLC, Austin
Lead Sponsor
AstraZeneca
INDUSTRY